CSL Stock Forecast for 2023 - 2025 - 2030
Updated on 05/01/2024
CSL Stock Forecast and Price Target
According to five experts, who recently provided their 2024 price targets for CSL, the average price target is $203.16, with a high estimate of $220.41 and a low estimate of $151.13. That is a potential downside of approximately -26.59% from the last closing price of $276.76 on April, 2024. Even if not interested in CSL stock, you may want to be aware of its competitors.
-26.59% Downside
CSL Fair Value Forecast for 2023 - 2025 - 2030
CSL's Price has decreased In the last four years, from $254.10 to $0.00 – a 100.00% drop. Analysts predict that CSL's Fair Value will increase in the upcoming year, reaching $337.15. This would represent an increase of 100.00%. Over the next seven years, experts predict that CSL's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr902.60 | Buy/Sell | kr696.07 | 6.36% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$144.59 | Buy/Sell | $174.55 | 17.57% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$129.22 | Buy/Sell | $130.51 | 10.66% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£120.62 | Buy/Sell | £165.99 | 35.09% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF89.05 | Buy/Sell | CHF105.00 | 20.85% |
CSL Revenue Forecast for 2023 - 2025 - 2030
In the last three years, CSL's Revenue has seen an increase, rising from $9.15B to $13.31B. This represents a growth of 45.45%. Analysts predict that CSL's Revenue will increase in the upcoming year, reaching $14.76B. This would represent an increase of 10.89%. Over the next seven years, experts predict that CSL's Revenue will grow at a rate of 86.54%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$105.97 | Buy/Sell | $118.92 | 19.37% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.62 | Buy/Sell | $32.87 | 19.05% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
93.08€ | Buy/Sell | 102.80€ | 17.10% |
.jpg)
CSL Dividend per Share Forecast for 2023 - 2025 - 2030
CSL's Dividend per Share has seen growth In the last three years, going from $2.02 to $2.36 – a gain of 16.83% In the next year, analysts believe that Dividend per Share will reach $2.65 – an increase of 12.29%. For the next seven years, the forecast is forDividend per Share to grow by 140.68%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$392.81 | Buy/Sell | $457.59 | 14.56% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.73 | Buy/Sell | £17.30 | 16.56% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.20 | Buy/Sell | $87.82 | 22.70% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.15k | Buy/Sell | ¥4.74k | 9.56% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$214.82 | Buy/Sell | $299.62 | 34.30% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
27.35€ | Buy/Sell | 45.15€ | 9.69% |
CSL EBITDA Forecast for 2023 - 2025 - 2030
CSL's EBITDA has grown in the last three years, jumping from $3.00B to $3.88B – an increase of 29.38%. In the next year, analysts predict that EBITDA will reach $4.92B – an increase of 26.90%. For the next eight years, the forecast is for EBITDA to grow by 115.02%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| UCB Stock Forecast | UCB | Outperform |
18
|
124.55€ | Buy/Sell | 102.66€ | 1.97% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.37 | Buy/Sell | $44.86 | 11.47% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.51k | Buy/Sell | ¥2.64k | 33.75% |
CSL EBIT Forecast for 2023 - 2025 - 2030
In the last three years, CSL's EBIT has increased by 19.75%, going from $2.72B to $3.25B. In the next year, analysts are expecting an increase in EBIT, predicting it will reach $4.19B – an increase of 28.82%. The CSL forecast is for EBIT to reach $7.86B or grow by 141.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SOBI Stock Forecast | Swedish Orphan Biovitrum AB (p... | Outperform |
16
|
kr285.40 | Buy/Sell | kr293.00 | 13.88% |
| 002252 Stock Forecast | Shanghai RAAS Blood Products | Buy |
18
|
¥7.18 | Buy/Sell | ¥9.08 | -2.51% |
| 600161 Stock Forecast | Beijing Tiantan Biological Pro... | Outperform |
18
|
¥28.77 | Buy/Sell | ¥31.28 | 10.74% |
CSL EPS Price Prediction Forecast for 2023 - 2025 - 2030
CSL's EPS has decreased In the last four years, from $4.62 to $0.00 – a 100.00% drop. Analysts predict that CSL's EPS will increase in the upcoming year, reaching $6.13. This would represent an increase of 100.00%. Over the next seven years, experts predict that CSL's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GRF Stock Forecast | Grifols | Outperform |
18
|
8.65€ | Buy/Sell | 18.48€ | 119.65% |
| 002007 Stock Forecast | Hualan Biological Engineering | Outperform |
18
|
¥19.47 | Buy/Sell | ¥25.89 | 34.05% |
| ITRI Stock Forecast | Itron | Outperform |
14
|
$92.12 | Buy/Sell | $77.33 | 12.90% |
.jpg)